Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Sarcoma

Presenters

Amandine Crombe

Citation

Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283

Authors

A. Crombe1, M. Kind1, I.L. Ray-Coquard2, N. Isambert3, C.M. Chevreau4, T. Andre5, C. Lebbe6, A. Le Cesne7, E. Bompas8, S. Piperno-Neumann9, E. Saada-Bouzid10, J. Blay11, A. Italiano12

Author affiliations

  • 1 Radiology Department, Bergonie Institute, 33000 - Bordeaux/FR
  • 2 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 3 Medical Oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 4 Medical Oncology, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 5 Medical Oncology, Hopital Saint-Antoine, 75571 - Paris/FR
  • 6 Medical Oncology, Hôpital Saint Louis, 75010 - Paris/FR
  • 7 Medical Oncology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 8 Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 9 Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 10 Medical Oncology, Hopital Lacassagne, 06100 - Nice/FR
  • 11 Medicine, Centre Léon Bérard, 69008 - Lyon/FR
  • 12 Early Phase Trials Unit, Institute Bergonié, 33076 - Bordeaux/FR
More

Resources

Abstract 4558

Background

Response of desmoid tumors (DT) to chemotherapy (CT) is evaluated according to RECIST criteria in daily practice and clinical trials. However, MRI demonstrates early change in heterogeneity in responding tumor, due to decrease in cellular area and increase in fibro-necrotic content, before dimensional response. Heterogeneity can be quantified through radiomics approach. Aim was to develop radiomics-based response criteria and to compare their performances with usual criteria.

Methods

43 patients (28 women, median age: 38.2) were prospectively included in this ancillary multicentre study of a randomized phase II trial (NCT01876082) as they presented with progressive DT, contrast-enhanced MRI at baseline (MRI-0) and early evaluation (3 months later, MRI-1). After signal intensities normalization, voxel size standardization and segmentation of whole DT volume on fat-suppressed contrast-enhanced T1-weighted imaging, 90 baseline and delta 3D-radiomics features (RF) were extracted. Using least absolute shrinkage and selection operator with Cox regression model and cross validation, a radiomics score based on selected and weighted RF was generated. The performances of prognostic models based on radiomics score, RECIST, mRECIST, EASL, Cheson, Choi and modified-Choi criteria from MRI-0 to MRI-1 to predict progression-free survival (PFS) were assessed with concordance-index. All the results were adjusted for ECOG performance status, initial tumor volume, prior CTs, current CT and B-catenin mutation. Usual response criteria were evaluated in both disease control and objective response settings.

Results

There were 11 progressions. The radiomics score included 4 variables (1 baseline RF and 3 delta-RF). A high radiomics score indicated a poorer prognosis. The radiomics score significantly correlated with PFS (adjusted hazard ratio = 3.39, 95%CI = [1.47-7.79], p = 0.0043) while none of the usual response criteria was (range of p-values = [0.166-0.750]). The prognostic model based on radiomics score had the highest concordance-index (0.794, 95%CI = [0.678-0.910]).

Conclusions

Quantifying heterogeneity with MRI at baseline and its early change through a dedicated radiomics score can improve the response evaluation for DT treated with CT.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Antoine Italiano.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.